Evidence map›Paper›PMID 37061603›Full record

ArticleScientific reports2023

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort.

Carlos Daniel Rodríguez-Ariza, Alfredo Cabrera-Villamizar, Astrid Lorena Rodríguez-Pulido, Santiago Callegari, Natalia Alejandra Ossa Rodríguez, Mónica Pinilla-Roncancio, Sergio Mauricio Moreno López, Carlos Andrés Sánchez-Vallejo

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Carlos Daniel Rodríguez-ArizaCritical Care Section, Internal Medicine Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Alfredo Cabrera-VillamizarCritical Care Section, Internal Medicine Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Astrid Lorena Rodríguez-PulidoInternal Medicine Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Santiago CallegariFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia.
Natalia Alejandra Ossa RodríguezFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia.
Mónica Pinilla-RoncancioFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia.
Sergio Mauricio Moreno LópezFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia.
Carlos Andrés Sánchez-VallejoFaculty of Medicine, Universidad de los Andes, Bogotá, Colombia. carlos.sanchez@fsfb.org.co.
Universidad de Los Andes · COFundación Santa Fe de Bogotá · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No cardiovascular risk score has included Latin American patients in its development. The ACC/AHA ASCVD risk score has not been validated in Latin America; consequently, its predictive capacity in the population of the region is unknown. The aim of this study is to evaluate the discrimination capacity and calibration of the ACC/AHA ASCVD score to predict the 10-year risk of a cardiovascular event in a primary prevention cohort followed in a Colombian hospital. A retrospective cohort study was conducted in primary prevention patients belonging to an intermediate/high-risk and low-risk cohort without established atherosclerotic disease. Cardiovascular risk was calculated at inclusion. The calibration was analyzed by comparing observed and expected events in the different risk categories. A discrimination analysis was made using the area under the ROC curve and C statistic. A total of 918 patients were included-202 from the intermediate/high-risk and 716 from the low-risk cohort. The median cardiovascular risk was 3.6% (IQR 1.7-8.5%). At the 10-year follow-up, 40 events (4,4%) occurred. The area under the ROC curve was 0.782 (95% CI 0.71-0.85). The Hosmer-Lemeshow test did not show differences between expected and observed events. The ACC/AHA ASCVD score is calibrated and has good discrimination capacity in predicting 10-year risk of cardiovascular events in a Colombian population.

Indexed as

AtherosclerosisCardiovascular DiseasesColombiaHumansRetrospective StudiesRisk AssessmentRisk Factors

Identifiers

PMID37061603
PMCPMC10105759
OpenAlexW4365815844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.